Summary & Overview
HCPCS J7645: Ipratropium Bromide Inhalation Solution, Compounded, DME Unit-Dose
HCPCS Level II code J7645 denotes ipratropium bromide in a compounded inhalation solution, supplied in unit-dose form and intended for administration via durable medical equipment. The code is used to bill for per-milligram doses of a compounded ipratropium formulation when delivered through nebulizers or other DME in home or outpatient settings. This designation matters nationally because it clarifies billing for compounded inhalation therapies that are outside standard commercial single-entity vial or cartridge products, affecting coverage and payment across payers.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise outline of the clinical context for ipratropium inhalation therapy, the service setting implications for DME administration, and the types of benchmarks and policy considerations typically addressed for J-codes and compounded products. The publication highlights billing nuances for compounded inhalation solutions, payer coverage landscapes, and where policy updates or clarifications are commonly needed. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J7645 represents ipratropium bromide, inhalation solution, compounded product, administered through DME, unit dose form, per milligram. This code describes a compounded inhalation medication formulation of ipratropium bromide provided in unit-dose format and intended for administration using durable medical equipment (DME).
-
Service type: DME-administered compounded inhalation medication
-
Typical site of service: Home or outpatient settings where DME is used for aerosolized or nebulized medication administration
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic obstructive pulmonary disease (COPD) or acute bronchospasm who requires inhaled anticholinergic therapy administered as a compounded unit-dose solution via durable medical equipment (nebulizer). The clinician (pulmonologist, primary care physician, or emergency medicine provider) prescribes J7645 when ipratropium bromide inhalation solution is prepared in unit-dose form and supplied for administration through DME. The workflow: assessment and indication for inhaled anticholinergic therapy; prescription and compounding specification documented in the medical record; verification of DME suitability and instruction for nebulizer use; pharmacy compounds the unit-dose ipratropium solution per the order; DME supplier dispenses unit-dose vials with administration instructions; follow-up visit or telehealth encounter documents response, adverse effects, and ongoing need. Typical sites of service include outpatient infusion/respiratory therapy clinics, hospital outpatient departments, emergency departments, and patient homes when DME is used for home nebulization.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Default when no modifier applies |
22 | Increased procedural services | Use when additional work or complexity in compounding/documentation is unusually greater than typical |
23 | Unusual anesthesia | Not typically applicable but included for completeness when procedural sedation/anesthesia is required for administration |
52 | Reduced services | Use when only partial dispensing or reduced quantity of the compounded product is provided |
53 | Discontinued procedure | Use if the compounding or administration is started but stopped before completion for patient-related reasons |
54 | Surgical care only | Not typically applicable; use only if surgical encounter is billed separate from drug/DME supply |
55 | Postoperative management only | Not typically applicable to this drug supply code |
56 | Preoperative management only | Not typically applicable to this drug supply code |
62 | Two surgeons | Rarely applicable; use only when two providers share administration responsibilities requiring separate attribution |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery | Rare for this code; use when applicable in an operative setting |
QK | Medical direction of two, three, or four concurrent anesthesia procedures involving qualified individuals | Not typical for this code; included for completeness |
QX | Qualified nonphysician anesthetist with medical direction | Not typical; include only if anesthesia personnel are involved in administration |
QY | Medical direction of one certified registered nurse anesthetist (CRNA) by an anesthesiologist | Not typical; include only if anesthesia personnel are involved |
SH | Speech-language pathologist services | Not applicable clinically; included because present in raw modifier list |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RC0000X | Pulmonology | Common prescribers for inhaled anticholinergic therapy and outpatient management of COPD/asthma |
207L00000X | Allergy & Immunology | Prescribe and manage inhaled therapies for reactive airways disease |
207Q00000X | Critical Care Medicine | Manage acute bronchospasm in inpatient and emergency settings where DME-administered solutions are used |
208D00000X | Family Medicine | Primary care prescribers who manage chronic respiratory disease and coordinate home DME |
3336C0002X | Respiratory Therapy | Clinicians who provide education, administration oversight, and DME support for nebulized therapies |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
J44.9 | Chronic obstructive pulmonary disease, unspecified | Common indication for anticholinergic inhalation therapy to reduce bronchospasm and improve airflow |
J45.909 | Unspecified asthma, uncomplicated | Short-acting anticholinergic agents may be used as adjunctive bronchodilator therapy in acute exacerbations |
J96.00 | Acute respiratory failure, unspecified whether with hypoxia or hypercapnia | Nebulized anticholinergics may be used as part of treatment for bronchospasm contributing to respiratory failure in monitored settings |
J98.011 | Acute bronchospasm | Direct indication for nebulized bronchodilator therapy including ipratropium solution |
R06.2 | Wheezing | Symptom prompting administration of inhaled bronchodilators including ipratropium via nebulizer |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
94640 | Pressurized or non-pressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes (e.g., nebulizer therapy) | Often performed concurrently when ipratropium inhalation solution is administered by nebulizer in clinic or emergency settings |
94664 | Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device | Education and device technique training provided when dispensing unit-dose ipratropium for home nebulizer use |
99070 | Supplies and materials (except spectacles), provided by the physician over and above those usually included with the office visit | May be used for additional sundries or non-covered supplies related to administration when applicable |
E1399 | Durable medical equipment, miscellaneous (HCPCS Level II) | Used by DME suppliers to bill related nebulizer devices or accessories not otherwise specified when supplying J7645 |
94060 | Bronchospasm evaluation with spirometry before and after bronchodilator (may be coded for pre/post-assessment) | Pulmonary function testing to document response to inhaled bronchodilator therapy in follow-up care |